secwatch.observer — SEC 8-K summary
======================================

Issuer:     Disc Medicine, Inc. (IRON)
CIK:        0001816736
Form:       8-K
Filed at:   2024-11-04T23:59:59+00:00
Accession:  0000950170-24-120292
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Disc Medicine gets FDA alignment on Phase 3 plan for bitopertin in EPP; accelerated approval possible
--------------------------------------------------------------------------------

- FDA agreed on all APOLLO trial parameters: single placebo-controlled study, 60 mg dose, 6-month duration, primary endpoint of monthly sunlight time without pain.
- Potential for accelerated approval using PPIX reduction as surrogate endpoint, allowing NDA submission based on existing data.
- APOLLO trial to include EPP and XLP patients aged 12+; initiation planned by mid-2025.
- Company to meet FDA to finalize details; update on NDA timing expected Q1 2025.
- Positive FDA feedback provides clear registration path for bitopertin in erythropoietic protoporphyria.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1816736/000095017024120292/0000950170-24-120292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1816736/000095017024120292/iron-20241104.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-120292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer